Nanoparticles as drug delivery systems

Pharmacological Reports

Volumn 64, Issue 5, 2012, Pages 1020-1037

  Wilczewska, Agnieszka Z ^a   Niemirowicz, Katarzyna ^b   Markiewicz, Karolina H ^a   Car, Halina ^a  

^a UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Drug delivery system; Magnetic nanoparticles; Nanocarriers; Nanoparticles; Targeting therapy

Indexed keywords

AMINOLEVULINIC ACID; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BETA LACTAM ANTIBIOTIC; CAPECITABINE; CARBON NANOHORN; CARBON NANOTUBE; CARBOPLATIN; CLOTRIMAZOLE; CYCLOSPORIN A; DENDRIMER; DOXORUBICIN; FLUOROURACIL; LAMIVUDINE; LIPID DRUG CONJUGATE; LIPOSOME; MAGNETIC NANOPARTICLE; MITOMYCIN; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; POLYMER; RETINOL ACETATE; RIFAMPICIN; SILICON DIOXIDE; SINGLE WALLED NANOTUBE; SOLID LIPID NANOPARTICLE; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; BIOCOMPATIBILITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; ENCAPSULATION; HUMAN; HYDROPHOBICITY; NEPHROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; STATIC ELECTRICITY; SYSTEMIC MYCOSIS;

EID: 84873643357     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70901-5     Document Type: Review

References (178)

1. Abdel-Mottaleb MMA, Neumann D, Lamprecht A: Lipid nanocapsules for dermal application: A comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm, 2011, 79, 36-42.
2. Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, Golomb G: Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release, 2008, 132, 84-90.
3. Agnihotri SA, Aminabhavi TM: Novel interpenetrating network chitosan-poly(ethylene oxide-g-acrylamide)hydrogel microspheres for the controlled release of capecitabine. Int J Pharm, 2006, 324, 103-115. (Pubitemid 44528908)
4. Ahola MS, Säilynoja ES, Raitavuo MH, Vaahtio MM, Salonen JI, Yli-Urpo AU: In vitro release of heparin from silica xerogels. Biomaterials, 2001, 22, 2163-2170. (Pubitemid 32738760)
5. Ai J, Biazar E, Montazeri M, Majdi A, Aminifard S, Safari M, Akbari HR: Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine, 2011, 6, 1117-1127.
6. Ajima K, Murakami T, Mizoguchi Y, Tsuchida K, Ichihashi T, Iijima S, Yudasaka M: Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS Nano, 2008, 2, 2057-2064.
7. Amato G: Silica-encapsulated efficient and stable si quantum dots with high biocompatibility. Nanoscale Res Lett, 2010, 5, 1156-1160.
8. Arayachukeat S, Wanichwecharungruang SP, Tree-Udom T: Retinyl acetate-loaded nanoparticles: Dermal penetration and release of the retinyl acetale. Int J Pharm, 2011, 404, 281-288.
9. Arias JL, López-Viota M, Delgado AV, Ruiz MA: Iron/ethylcellulose (core/shell) nanoplatform loaded with 5-fluorouracil for cancer targeting. Colloids Surf B Biointerfaces, 2010, 77, 111-116.
10. Arruebo M, Fernández-Pacheco R, Ibarra, MR, Santamaría J: Magnetic nanoparticles for drug delivery. Nano Today, 2007, 2, 22-32. (Pubitemid 46695431)
11. Arsawang U, Saengsawang O, Rungrotmongkol T, Sornmee P, Wittayanarakul K, Remsungnen T, Hannongbua S: How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system? J Mol Graph Model, 2011, 29, 591-596.
12. Asmatulu R, Zalich MA, Claus RO, Riffle J: Synthesis, characterization and targeting of biodegradable magnetic nanocomposite particles by external magnetic fields. J Magn Magn Mater, 2005, 292, 108-119. (Pubitemid 40423107)
13. Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC: Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization. Eur J Pharm Biopharm, 2007, 67, 48-57. (Pubitemid 46991314)
14. Bai J, Li Y, Du J, Wang S, Zheng J, Yang O, Chen X: One-pot synthesis of polyacrylamide-gold nanocomposite. Mater Chem Phys, 2007, 106, 412-415. (Pubitemid 47599753)
15. Bajpai AK, Gupta R: Magnetically mediated release of ciprofloxacin from polyvinyl alcohol based superparamagnetic nanocomposites. J Mater Sci Mater Med, 2011, 22, 357-369.
16. Balogh L, Swanson DR, Tomalia DA, Hagnauer GL, McManus AT: Dendrimer-silver complexes and nanocomposites as antimicrobial agents. Nano Lett, 2001, 1, 18-21. (Pubitemid 33672965)
17. Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, Kohli K: Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol, 2011, 63, 141-163.
18. Bhirde AA, Patel S, Sousa AA, Patel V, Molinolo AA, Ji Y, Leapman RD et al.: Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine, 2010, 5, 1535-1546.
19. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD et al.: Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano, 2009, 3, 307-316.
20. Bilensoy E, Sarisozen C, Esendagl G, Dogan LA, Aktas Y, Sen M, Mangan AN: Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm, 2009, 371, 170-176.
21. Biswas S, Dodwadkar NS, Deshpande PP, Torchilin VP: Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release, 2012, 159, 393-402.
22. Biswas S, Dodwadkar NS, Sawant RR, Torchilin VP: Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization. Bioconjug Chem, 2011, 22, 2005-2013.
23. Caminade AM, Laurent R, Majoral JP: Characterization of dendrimers. Adv Drug Deliv Rev, 2005, 57, 2130-2146. (Pubitemid 41759390)
24. Cao Q, Han X, Li L: Enhancement of the efficiency of magnetic targeting for drug delivery: Development and evaluation of magnet system. J Magn Magn Mater, 2011, 323, 1919-1924.
25. Chang JH, Kang KH, Choi J, Jeong YK: High efficiency protein separation with organosilane assembled silica coated magnetic nanoparticles. Superlattice Microst, 2008, 44, 442-448.
26. Chauhan AS, Diwan PV, Jain NK, Tomalia DA: Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules, 2009, 10, 1195-1202.
27. Chauhan AS, Jain NK, Diwan PV: Pre-clinical and behavioural toxicity profile of PAMAM dendrimers in mice. Proc R Soc A, 2010, 466, 1535-1550.
28. Chen JP, Yang PC, Ma YH, Wu T: Characterization of chitosan magnetic nanoparticles for in situ delivery of tissue plasminogen activator. Carbohydr Polym, 2011, 84, 364-372.
29. Chen M, von Mikecz A: Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. Exp Cell Res, 2005, 305, 51-62. (Pubitemid 40380653)
30. 2 nanoparticle inhalation: nanotoxicity has susceptible population. Environ Sci Technol, 2008, 42, 8985-8992.
31. Chen Z, Pierre D, He H, Tan S, Pham-Huy C, Hong H, Huang J: Adsorption behavior of epirubicin hydrochloride on carboxylated carbon nanotubes. Int J Pharm, 2011, 28, 405, 153-161.
32. Cho M, Cho WS, Choi M, Kim SJ, Han BS, Kim SH, Kim HO et al.: The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett, 2009, 189, 177-183.
33. Cho WS, Choi M, Han BS, Cho M, Oh J, Park K, Kim SJ et al.: Inflammatory mediators induced by intratracheal instillation of ultrafine amorphous silica particles. Toxicol Lett, 2007, 175, 24-33. (Pubitemid 350116475)
34. Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R, Hubalem J: Magnetic nanoparticles and targeted drug delivering. Pharm Res, 2010, 62, 144-149.
35. Cole AJ, Yang VC, David AE: Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol, 2011, 29, 323-332.
36. Czarnobaj K: Preparation and characterization of silica xerogels as carriers for drugs. Drug Deliv, 2008, 15, 485-492.
37. Czarnobaj K, Czarnobaj J: Sol-gel processed porous silica carriers for the controlled release of diclofenac diethylamine. J Biomed Mater Res B Appl Biomater, 2008, 87, 114-120.
38. Czarnobaj K, Lukasiak J: In vitro release of cisplatin from sol-gel processed organically modified silica xerogels. J Mater Sci Mate Med, 2007, 18, 2041-2044. (Pubitemid 47421899)
39. 5 composites doped with metronidazole for application in local delivery systems. Pharm Dev Technol, 2011, (doi: 10.3109/10837450.2011. 572894).
40. D'Emanuele A, Attwood D: Dendrimer-drug interactions. Adv Drug Deliv Rev, 2005, 57, 2147-2162. (Pubitemid 41760432)
41. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA, Scherphof GL: Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer, 1995, 61, 666-671.
42. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V: Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release, 2006,116, 1-27. (Pubitemid 44792295)
43. Dev A, Binulal NS, Anita A, Nair SV, Furuike T, Tamura H, Jayakumar R: Preparation of poly(lactic acid)/chitosan nanoparticles for anti-HIV drug delivery applications. Carbohydr Polym, 2010, 80, 833-838.
44. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ: Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc, 2008, 27, 130, 11467-11476.
45. Di Crescenzo A, Velluto D, Hubbell JA, Fontana A: Biocompatible dispersions of carbon nanotubes: a potential tool for intracellular transport of anticancer drugs. Nanoscale, 2011, 3, 925-928.
46. Di Pasqua AJ, Wallner S, Kerwood DJ, Dabrowiak JC: Adsorption of the Pt(II) anticancer drug carboplatin by mesoporous silica. Chem Biodiv, 2009, 6, 1343-1349.
47. Dobrovolskaia MA, McNeil SE: Immunological properties of engineered nanomaterials. Nat Nano, 2007, 2, 469-478. (Pubitemid 47220069)
48. dos Santos Giuberti C, de Oliveira Reis EC, Ribeiro Rocha TG, Leite EA, Lacerda RG, Ramaldes GA, de Oliveira MC: Study of the pilot production process of long-circulating and pH-sensitive liposomes containing cisplatin. J Liposome Res, 2011, 21, 60-69.
49. Duncan R, Izzo L: Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev, 2005, 57, 2215-2237. (Pubitemid 41759394)
50. Echeverría JC, Estella J, Barbería V, Musgo J, Garrido JJ: Synthesis and characterization of ultramicroporous silica xerogels. J Non-Cryst Solids, 2010, 356, 378-382.
51. Eom HJ, Choi J: Oxidative stress of silica nanoparticles in human bronchial epithelial cell, Beas-2B. Toxicol In Vitro, 2009, 23, 1326-1332.
52. Fidalgo A, Lopez TM, Ilharco LM: Wet sol-gel silica matrices as delivery devices for phenytoin. J Sol-Gel Sci Technol, 2009, 49, 320-328.
53. Figuerola A, Di Corato R, Manna L, Pellegrino T: From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res, 2010, 62, 126-143.
54. Foldvari M, Bagonluri M: Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomedicine, 2008, 4, 173-182.
55. Fritzen-Garcia MB, Zanetti-Ramos BG, Schweitzer de Oliveira C, Soldi V, Pasa AA, Creczynski-Pasa TB: Atomic force microscopy imaging of polyurethane nanoparticles onto different solid. Mater Sci Eng C, 2009, 29, 405-409.
56. Gaihre B, Khil MS, Lee DR, Kim HY: Gelatin-coated magnetic iron oxide nanoparticles as carrier system: drug loading and in vitro drug release study. Int J Pharm, 2009, 365, 180-189.
57. Grassi-Schultheiss PP, Heller F, Dobson J: Analysis of magnetic material in the human heart, spleen and liver. Biometals, 1997, 10, 351-355. (Pubitemid 27464326)
58. Hafeli UO, Riffle JS, Harris-Shekhawat L, Carmichael-Baranauskas A, Mark F, Dailey JP, Bardenstein D: Cell uptake and in vitro toxicity of magnetic nanoparticles suitable for drug delivery. Mol Pharm, 2009, 6, 1417-1428.
59. Han L, Huang R, Liu S, Huang S, Jiang Ch: Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm, 2010, 7, 2156-2165.
60. He Q, Gao Y, Zhang L, Zhang Z, Gao F, Ji X, Li Y, Shi J: A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials, 2011, 32, 7711-7720.
61. Heiden TCK, Dengler E, Kao WJ, Heideman W, Peterson DE: Developmental toxicity of low generation PAMAM dendrimers in zebrafish. Toxicol Appl Pharmacol, 2007, 225, 70-79. (Pubitemid 350016213)
62. Hocine O, Gary-Bobo M, Brevet D, Maynadier M, Fontanel S, Raehm L, Richeter S et al.: Silicalites and mesoporous silica nanoparticles for photodynamic therapy. Int J Pharm, 2010, 402, 221-230.
63. Hong S, Bielinska AU, Mecke A, Keszler B, Beals JL, Shi X, Balogh L et al.: Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem, 2004, 15, 774-782. (Pubitemid 38981951)
64. Hua MY, Liu HL, Yang HW, Chen PY, Tsai RY, Huang CY, Tseng IC et al.: The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials, 2011, 32, 516-527.
65. Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, Chuang KL, Chang YH et al.: Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials, 2010, 31, 7355-7363.
66. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V: Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm, 2007, 5, 316-327.
67. Jia G, Wang H, Yan L, Wang X, Pei R, Yan T, Zhao Y, Guo X: Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ Sci Technol, 2005, 39, 1378-1383. (Pubitemid 40333400)
68. 4-dextran-anti-β-human chorionic gonadotropin, a new generation choriocarcinoma-specific gene vector. Int J Nanomedicine, 2011, 6, 285-294.
69. 4 nanoparticles for applications in hyperthermia and drug delivery. Nanomedicine, 2012, 8, 452-459.
70. Karlsson HL, Cronholm P, Gustafsson J, Moller L: Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. Chem Res Toxicol, 2008, 21, 1726-1732.
71. Kempe H, Kempe M: The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. Biomaterials, 2010, 31, 9499-9510.
72. Kim JK, Choi SH, Kim CO, Park JS, Ahn WS, Kim CK: Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency. J Pharm Pharmacol, 2003, 55, 453-460.
73. Kim TW, Slowing II, Chung PW, Lin VS: Ordered mesoporous polymer-silica hybrid nanoparticles as vehicles for the intracellular controlled release of macromolecules. ACS Nano, 2011, 5, 360-366.
74. Kitchens KM, Kolhatkar RB, Swaan PW, Eddington ND, Ghandehari H.: Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling. Pharm Res, 2006, 23, 2818-2826. (Pubitemid 44885368)
75. Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K: Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm, 2010, 383, 293-296.
76. Kovacevic A, Savic S, Vuleta G, Müller RH, Keck CM: Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure. Int J Pharm, 2011, 406, 163-172.
77. Kumar R, Roy I, Ohulchanskky TY, Vathy LA, Bergey EJ, Sajjad M, Prasad PN: In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano, 2010, 4, 699-708.
78. Kumari A, Yadav SK, Yadav SC: Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces, 2010, 75, 1-18.
79. Lai J, Lu Y, Yin Z, Hu F, Wu W: Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine, 2010, 5, 13-23.
80. Lam CW, James JT, McCluskey R, Hunter RL: Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci, 2004, 77, 126-134. (Pubitemid 38128652)
81. Li Z, Su K, Cheng B, Deng Y: Organically modified MCM-type material preparation and its usage in controlled amoxicillin delivery. J Colloid Interface Sci, 2010, 342, 607-613.
82. Lin W, Huang YW, Zhou XD, Ma Y: In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol, 2006, 217, 252-259. (Pubitemid 44855825)
83. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z: Solid lipid nanoparticles for pulmonary delivery of insulin, Int J Pharm, 2008, 356, 333-344.
84. Liu X, Sun J: Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways. Biomaterials, 2010, 31, 8198-8209.
85. Lope AL, Reins RY, McDermott AM, Trautner BW, Cai C: Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. Mol Biosyst, 2009, 5, 1148-1156.
86. Losic D, Yu Y, Aw MS, Simovic S, Thierry B, Addai-Mensah J: Surface functionalisation of diatoms with dopamine modified iron-oxide nanoparticles: toward magnetically guided drug microcarriers with biologically derived morphologies. Chem Commun (Camb), 2010, 46, 6323-6325.
87. Luo G, Yu X, Jin C, Yang F, Fu D, Long J, Xu J et al.: LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm, 2010, 385, 150-156.
88. Luo X, Matranga C, Tan S, Alba N, Cui XT: Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone. Biomaterials, 2011, 32, 6316-6323.
89. Mahmoudi M, Simchi A, Imani M, Shokrgozar MA, Milani AS, Hafeli U, Stroeve P: A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. Colloids Surf B Biointerfaces, 2010, 75, 300-309.
90. Mahmoudi M, Simchi A, Milani AS, Stroeve P: Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci, 2009, 336, 510-518.
91. Mainardes RM, Khalil NM, Gremiǎ;o MPD: Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. Int J Pharm, 2010, 395, 266-271.
92. Malik N, Evagorou EG, Duncan R: Dendrimer-platinate: a novel approach to cancer chemotherapy. Anti-Cancer Drugs Des, 1999, 10, 767-776. (Pubitemid 30015678)
93. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang J, August JT, Leong KW: Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release, 2001, 70, 399-421. (Pubitemid 32155463)
94. Martinem A, Iglesias I, Lozano R, Teijon JM, Blanco MD: Synthesis and characterization of thiolated alginate-albumin nanoparticles stabilized by disulfide bonds. Evaluation as drug delivery systems. Carbohydr Polym, 2011, 83, 1311-1321.
95. Maver U, Godec A, Bele M, Planinšek O, Gaberšček M, Srčič S, Jamnik J: Novel hybrid silica xerogels for stabilization and controlled release of drug. Int J Pharm, 2007, 330,164-174. (Pubitemid 46097367)
96. Meng X, Seton HC, Lu le T, Prior IA, Thanh NT, Song B: Magnetic CoPt nanoparticles as MRI contrast agent for transplanted neural stem cells detection. Nanoscale, 2011, 3, 977-984.
97. Menjoge AR, Kannan RM, Tomalia DA: Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today, 2010, 15, 171-187.
98. Monteiro-Riviere NA, Nemanich RJ, Inman AO, Wang YY, Riviere JE: Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol Lett, 2005, 155, 377-384. (Pubitemid 40093001)
99. Mora-Huertas CE, Fessi H, Elaissari A: Polymer-based nanocapsules for drug delivery. Int J Pharm, 2010, 385, 113-142.
100. Muchow M, Maincent P, Müller RH: Lipid nanoparticles with a solid matrix (SLN, NLC LDC) for oral drug delivery. Drug Dev Ind Pharm, 2008, 34, 1394-1405.
101. Muller J, Huaux F, Moreau N, Misson P, Heilier JF, Delos M, Arras M et al.: Respiratory toxicity of multi-wall carbon nanotubes. Toxicol Appl Pharmacol, 2005, 207, 221-231. (Pubitemid 41207915)
102. Müller RH, Keck CM: Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol, 2004, 113, 151-170. (Pubitemid 39237077)
103. Müller RH, Petersen RD, Hommoss A, Pardeike J: Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev, 2007, 59, 522-530. (Pubitemid 47271894)
104. Müller RH, Radtke M, Wissing SA: Nanostructured lipid matrices for improved microencapsulation of drugs, Int J Pharm, 2002, 242, 121-128.
105. Murakami T, Sawada H, Tamura G, Yudasaka M, Iijima S, Tsuchida K: Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomedicine, 2008, 3, 453-463.
106. Nanjwade BK, Singh J, Parikh KA, Manvi FV: Preparation and evaluation of carboplatin biodegradable polymeric nanoparticles. Int J Pharm, 2010, 385, 176-180.
107. Naqvi S, Samim M, Abdin MZ, Ahmed FJ, Maitra AN, Prashant CK, Dinda AK: Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine, 2010, 5, 983-989.
108. Natali S, Mijovic J: Dendrimers as drug carriers: dynamics of PEGylated and methotrexate-loaded dendrimers in aqueous solution. Macromolecules, 2010, 43, 3011-3017.
109. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB: Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces, 2010, 81, 263-273.
110. Neuberger T, Schopf B, Hofmann H, Hofmann M, von Rechenberg B: Superpara-magnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater, 2005, 293, 483-496. (Pubitemid 40608969)
111. Nevozhay D, Kańska U, Budzyńska R, Boratyński J: Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases (Polish). Postepy Hig Med Dosw, 2007, 61, 350-360.
112. Nishimori H, Kondoh M, Isoda K, Tsunoda S, Tsutsumi Y, Yagi K: Silica nanoparticles as hepatotoxicants. Eur J Pharm Biopharm, 2009, 72, 496-501.
113. Paavola A, Kilpeläinen I, Yliruusi J, Rosenberg P: Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. Int J Pharm, 2000, 199, 85-93. (Pubitemid 30224508)
114. Pan BF, Gao F, Gu HC: Dendrimer modified magnetite nanoparticles for protein immobilization. J Colloid Interface Sci, 2005, 284, 1-6. (Pubitemid 40332441)
115. Pandey R, Ahmad Z, Sharma S, Khuller GK: Nanoencapsulation of azole antifungals: Potential applications to improve oral drug delivery. Int J Pharm, 2005, 301, 268-276. (Pubitemid 41206612)
116. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev, 2003, 55, 329-347. (Pubitemid 36297053)
117. Park EJ, Park K: Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol Lett, 2009, 184, 18-25.
118. Park J, Fong PM, Lu J, Russell KS, Booth KJ, Saltzman WM, Fahmy TM: PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine, 2009, 5, 410-418.
119. Perry JL, Martin CR, Stewart JD: Drug-delivery strategies by using template-synthesized nanotubes. Chemistry, 2011, 17, 6296-6302.
120. Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WA, Seaton A, Stone V et al.: Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol, 2008, 3, 423-428.
121. Popovici RF, Seftel EM, Mihai GD, Popovici E, Voicu VA: Controlled drug delivery system based on ordered mesoporous silica matrices of captopril as angiotensin-converting enzyme inhibitor drug. J Pharm Sci, 2011, 100, 704-714.
122. Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK: Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharm, 2009, 6, 940-950.
123. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S et al.: Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother, 2011, 66, 874-879.
124. Prokopowicz M: Synthesis and in vitro characterization of freeze-dried doxorubicin-loaded silica xerogels. J Sol-Gel Sci Technol, 2010, 53, 525-533.
125. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, Ricci M: Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm, 2008, 357, 295-304.
126. Quintanar-Guerrero D, Ganem-Quintanar A, Nava-Arzaluz MG, Pińón-Segundo E: Silica xerogels as pharmaceutical drug carriers. Expert Opin Drug Deliv, 2009, 6, 485-498.
127. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, Radomski MW: Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol, 2005, 146, 882-893. (Pubitemid 41622255)
128. Rejinold NS, Chennazhi KP, Nair SV, Tamura H, Jayakumar R: Biodegradable and thermo-sensitive chitosan-g-poly(N-vinylcaprolactam) nanoparticles as a 5-fluorouracil carrier. Carbohydr Polym, 2011, 83, 776-786.
129. Roberts JC, Bhalgat MK, Zera RT: Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res, 1996, 30, 53-65.
130. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN et al.: Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore), 2010, 89, 236-244.
131. Saraog GK, Gupta P, Gupta UD, Jain NK, Agrawal GP: Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm, 2010, 385, 143-149.
132. 4 nanoparticles. J Nanosci Nanotechnol, 2011, 11, 3363-3369.
133. Sayes CM, Liang F, Hudson JL, Mendez J, Guo W, Beach JM, Moore VC et al.: Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett, 2006, 161, 135-142. (Pubitemid 41790286)
134. Shah N, Steptoe RJ, Parekh HS: Low-generation asymmetric dendrimers exhibit minimal toxicity and effectively complex DANN. J Pept Sci, 2011, 17, 470-478.
135. Shi L, Fleming CJ, Riechers SL, Yin N-N, Luo J, Lam KS, Liu GY: High-resolution imaging of dendrimers used in drug delivery via scanning probe microscopy. J Drug Deliv, 2011, (doi:10.1155/2011/254095).
136. Shiba K, Yudasaka M, Iijima S: Carbon nanohorns as a novel drug carrier. Nihon Rinsho, 2006, 64, 239-246.
137. Shin US, Yoon IK, Lee GS, Jang WC, Knowles JC, Kim HW: Carbon nanotubes in nanocomposites and hybrids with hydroxyapatite for bone replacements. J Tissue Eng, 2011, (doi:10.4061/2011/674287).
138. Shubayev VI, Pisanic TR 2nd, Jin S: Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev, 2009, 61, 467-477.
139. Silva R, Ferreira H, Cavaco-Paulo A: Sonoproduction of liposomes and protein particles as templates for delivery purposes. Biomacromolecules, 2011, 12, 3353-3368.
140. Singh P, Gupta U, Asthana A, Jain NK: Folate and Folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjugate Chem, 2008, 19, 2239-2252.
141. Slowing I, Trewyn BG, Giri S, Lin VS-Y: Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mater, 2007, 17, 1225-1236. (Pubitemid 46847636)
142. Slowing I, Vivero-Escoto JL, Wu Ch-W, Lin VS-Y: Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev, 2008, 60, 1278-1288.
143. Smolensky ED, Park HY, Berquó TS, Pierre VC: Surface functionalization of magnetic iron oxide nanoparticles for MRI applications - effect of anchoring group and ligand exchange protocol. Contrast Media Mol Imaging, 2011, 6, 189-199.
144. Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE: Targeted nanoparticles for detecting and treating cancer. Drug Dev Res, 2006, 67, 70-93. (Pubitemid 43765051)
145. Suri SS, Fenniri H, Singh B: Nanotechnology-based drug delivery systems. J Occup Med Toxicol, 2007, 2, 16.
146. Svenson S, Tomalia DA: Dendrimers in biomedical applications - reflections on the field. Adv Drug Deliv Rev, 2005, 57, 2106-2129. (Pubitemid 41759389)
147. Sznitowska M, Gajewska M, Janicki S, Radwanska A, Lukowski G: Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm, 2001, 52, 159-163. (Pubitemid 32755894)
148. 4 - Au, nanoparticles for biomolecule immobilization and detection. J Nanopart Res, 2010, 12, 1187-1196.
149. Tanis I, Karatasos K: Association of a weakly acidic anti-inflammatory drug (Ibuprofen) with a poly(amidoamine) dendrimer as studied by molecular dynamics simulations. J Phys Chem B, 2009, 113, 10984-10993.
150. Tomalia DA: Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Prog Polym Sci, 2005, 30, 294-324.
151. Tong Q, Li H, Li W, Chen H, Shu X, Lu X, Wang G: In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system. J Nanosci Nanotechnol, 2011, 11, 3651-3658.
152. Torchilin V: Multifunctional Pharmaceutical Nanocarriers, Springer Science + Business Media, LLC, NY, 2008.
153. 14 receptor by a tethered nucleotide. Bioconjug Chem, 2010, 21, 372-384.
154. Tripisciano C, Costa S, Kalenczuk RJ, Borowiak-Palen E: Cisplatin filled multiwalled carbon nanotubes - a novel molecular hybrid of anticancer drug container. Eur Phys J B, 2010, 75, 141-146.
155. Turkova A, Roilides E, Sharland M: Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? Curr Opin Infect Dis, 2011, 24, 163-171.
156. Turos E, Shim JY, Wang Y, Greenhalgh K, Reddy GS, Dickey S, Lim DV: Antibiotic-conjugated polyacrylate nanoparticles: New opportunities for development of anti-MRSA agents. Bioorg Med Chem Lett, 2007, 17, 53-56. (Pubitemid 46001585)
157. Üner M, Yener G: Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2007, 2, 289-300. (Pubitemid 350047774)
158. van den Hoven JM, Van Tomme SR, Metselaar JM, Nuijen B, Beijnen JH, Storm G: Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm, 2011, 8, 1002-1015.
159. Waite CL, Roth ChM: PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem, 2009, 20, 1908-1916.
160. Wang J, Chen Y, Chen B, Ding J, Xia G, Gao C, Cheng J et al.: Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice. Int J Nanomedicine, 2010, 5, 861-866.
161. Wängler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W: Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the imunoreactivity. Bioconjug Chem, 2008, 19, 813-820. (Pubitemid 351614537)
162. Waters KM, Masiello LM, Zangar RC, Tarasevich BJ, Karin NJ, Quesenberry
163. Wei L, Hu N, Zhang Y: Synthesis of polymer-mesoporous silica nanocomposites. Materials, 2010, 3, 4066-4079.
164. Wilson B, Samanta MK, Santhi K, Kumar KP, Ramasamy M, Suresh B: Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine, 2010, 6, 144-152.
165. Wissing SA, Kayser O, Müller RH: Solid lipid nanopartic les for parenteral drug delivery. Adv Drug Deliv Rev, 2004, 56, 1257-1272. (Pubitemid 38510473)
166. Wu W, Chen B, Cheng J, Wang J, Xu W, Liu L, Xia G et al.: Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine, 2010, 5, 1079-1084.
167. Xiong F, Mi Z, Gu N: Cationic liposomes as gene delivery system: transfection efficiency and new application. Pharmazie, 2011, 66, 158-164.
168. Yallapu MM, Othman SF, Curtis ET, Gupta BK, Jaggi M, Chauhan SC: Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials, 2011, 32, 1890-1905.
169. Yang H, Wu Q, Tang M, Kong L, Lu Z: Cell membrane injury induced by silica nanoparticles in mouse macrophage. J Biomed Nanotechnol, 2009, 5, 528-535.
170. Yang J, Park SB, Yoon HG, Huh YM, Haam S: Preparation of poly ε-caprolactone nanoparticles containing magnetite for magnetic drug carrier. Int J Pharm, 2006, 324, 185-190. (Pubitemid 44528914)
171. Yeung CK, Shek SY, Yu CS, Kono T, Chan HH: Liposome-encapsulated 0.5% 5-aminolevulinic acid with intense pulsed light for the treatment of inflammatory facial acne: a pilot study. Dermatol Surg, 2011, 37, 450-459.
172. Yoo JW, Chambers E, Mitragotri S: Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des, 2010, 16, 2298-2307.
173. Yu H, Nie Y, Dohmen Ch, Li Y, Wagner E: Epidermal growth factor-PEG functionalized PAMAM-pentaethylenehexamine dendron for targeted gene delivery produced by click chemistry. Biomacromolecules, 2011, 12, 2039-2047.
174. Yu KO, Grabinski CM, Schrand AM, Murdock RC, Wang W, Gu B, Schlager JJ et al.: Toxicity of amorphous silica nanoparticles in mouse keratinocytes. J Nanopart Res, 2009, 11, 15-24.
175. Yukihara M, Ito K, Tanoue O, Goto K, Matsushita T, Matsumoto Y, Masuda M et al.: Effective drug delivery system for duchenne muscular dystrophy using hybrid liposomes including gentamicin along with reduced toxicity. Biol Pharm Bull, 2011, 34, 712-716.
176. Zhang B, Chen Q, Tang H, Xie Q, Ma M, Tan L, Zhang Y, Yao S: Characterization of and biomolecule immobilization on the biocompatible multi-walled carbon nanotubes generated by functionalization with polyamidoamine dendrimers. Colloids Surf B Biointerfaces, 2010, 80, 18-25.
177. Zhang D, Pan B, Wu M, Wang B, Zhang H, Peng H, Wu D, Ning P: Adsorption of sulfamethoxazole on functionalized carbon nanotubes as affected by cations and anions. Environ Pollut, 2011, 159, 2616-2621.
178. Zhao Y, Sun X, Zhang G, Trewyn BG, Slowing II, Lin VS: Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano, 2011, 5, 1366-1375.